Healthcare Innovation

Aggressive Sector Overweight

Biotech, genomics, and medical devices are at an inflection point. GLP-1 drugs alone represent a $100B+ market. This portfolio bets on healthcare being the next decade's growth story.

4
ETFs
0.9%
Aggregate Yield
$3.6B
Wtd Avg AUM

Holdings

Symbol Name Weight Price 1D 3M YTD Yield AUM
IYH iShares U.S. Healthcare ETF 30% $61.77 ... ... ... 1.3% $2.9B
ARKG ARK Genomic Revolution ETF 25% $26.68 ... ... ... — $1.0B
IBB iShares Biotechnology ETF 20% $169.39 ... ... ... 0.2% $8.2B
IHI iShares U.S. Medical Devices ETF 25% $53.23 ... ... ... 0.4% $3.2B

Investment Thesis

Healthcare is undergoing its most significant transformation since the Human Genome Project. GLP-1 receptor agonists (Ozempic, Mounjaro) have created a $100B+ obesity drug market from nearly nothing. CRISPR gene editing is moving from theory to approved therapies. AI is accelerating drug discovery timelines from decades to years. Medical devices are getting smarter with AI-powered diagnostics and robotic surgery. This portfolio layers exposure from large-cap healthcare (IYH) for stability, through cap-weighted biotech (IBB), genomics innovation (ARKG), and medical devices (IHI). The risk is real — biotech is binary (drugs either work or they don't), and regulatory changes can impact the entire sector. But the demographic tailwind of aging populations globally and the technology-driven revolution in how we develop treatments creates a compelling long-term opportunity.

Portfolio Construction

IYH iShares U.S. Healthcare ETF
30%
Large-cap healthcare anchor — the established players: UnitedHealth, Johnson & Johnson, Eli Lilly, Pfizer, Abbott. These companies generate massive cash flows and provide stability while the speculative positions develop.
Yield: 1.3% AUM: $2.9B
ARKG ARK Genomic Revolution ETF
25%
Genomic revolution and biotech innovation — ARK's actively managed fund targeting CRISPR therapies, gene editing, targeted oncology, and molecular diagnostics. High risk, high reward exposure to the cutting edge.
AUM: $1.0B
IBB iShares Biotechnology ETF
20%
Cap-weighted biotech for stability — market-cap weighting means the proven winners (Amgen, Gilead, Regeneron) dominate, providing a more stable base than equal-weight biotech approaches.
Yield: 0.2% AUM: $8.2B
IHI iShares U.S. Medical Devices ETF
25%
Medical devices — steady growth segment. Medtronic, Abbott, Intuitive Surgical, and Edwards Lifesciences. Less binary than pharma — devices have longer product cycles and recurring revenue from consumables.
Yield: 0.4% AUM: $3.2B

Key Considerations

  • Biotech stocks are extremely volatile — individual drug failures or regulatory setbacks can crash the sector
  • Political risk from drug pricing legislation or regulatory changes
  • Many biotech companies are unprofitable and burning cash — they need to raise capital or get acquired
  • Healthcare innovation can take decades to commercialize
← All Portfolios